Serum paraoxonase 1 activity status in patients with liver disorders

Saudi Journal of Gastroenterology

Volumn 16, Issue 2, 2010, Pages 79-83

  Kedage, Vivekananda ^a   Muttigi, Manjunatha S ^a   Shetty, Mahesh S ^a   Suvarna, Renuka ^a   Rao, Soumya S ^a   Joshi, Chitralekha ^a   Prakash, Mungli ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Acute viral hepatitis; Cirrhosis; Falciparum malaria; Left ventricular failure; Leptospirosis; Liver disease; Paraoxonase 1; Sepsis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BILIRUBIN; GLOBULIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE FAILURE; HUMAN; LEPTOSPIROSIS; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTIPLE ORGAN FAILURE; PORTAL HYPERTENSION; SEPSIS; SPECTROPHOTOMETRY; VIRUS HEPATITIS;

ACUTE DISEASE; ADULT; AGED; ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; LEPTOSPIROSIS; LIVER CIRRHOSIS; LIVER DISEASES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROGNOSIS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 77950545921     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.61232     Document Type: Article

References (32)

1. Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L, et al. Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002;48:261-268 (Pubitemid 34107262)
2. La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996;2:1186-1187
3. Çakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med 2008;8:51-57 (Pubitemid 351666852)
4. Sidlova K, Skalicka V, Kotaska K, Pechova M, Chada M, Bartsova J, et al. Serumα-glutathione S-transferase as a senstive marker of hepatocelluar damage in patients with cystic fibrosis. Physiol Res 2003;52:361-365 (Pubitemid 36740489)
5. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994;33:832-839
6. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. Arterioscler Thromb Vasc Biol 1997;17:2935-2939
7. Gonzalvo MC, Gil F, Hernández AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): Subcellular distribution and characterization. J Biochem Mol Toxicol 1998;12:61-69 (Pubitemid 128501118)
8. Burlina A, Galzigna L. Serum arylesterase isoenzymes in chronic hepatitis. Clin Biochem 1974;17:202-205
9. Burlina A, Michielin E, Galzigna L. Characteristics and behaviour of arylesterase in human serum and liver. Eur J Clin Invest 1977;7:17-20. (Pubitemid 8299886)
10. Kawai H, Sakamoto F, Inoue Y. Improved specific assay for serum arylesterase using a water-soluble substrate. Clin Chim Acta 1990;188:177-182 (Pubitemid 20150123)
11. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A 1995;92:7187-7191
12. Ferré N, Marsillach J, Camps J, Mackness B, Mackness M, Riu F, et al. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J Hepatol 2006;45:51-59 (Pubitemid 43850613)
13. Marsillach J, Ferré N, Vila MC, Lligoña A, Mackness B, Mackness M, et al. Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clin Biochem 2007;40:645-650 (Pubitemid 46839097)
14. Prakash M, Shetty JK, Tripathy S, Verma M, Vasudeva S, Bhandary VB. Serum paraoxonase in alcohol abusers associated with alcoholic liver disease. Clin Chim Acta 2007;378:232-234 (Pubitemid 46241086)
15. Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005;11:7351-7354 (Pubitemid 43137689)
16. Xu GY, Lv GC, Chen Y, Hua YC, Zhu SM, Yang YD. Monitoring the level of serum paraoxonase 1 activity in liver transplantation patients. Hepatobiliary Pancreat Dis Int 2005;4:178-181 (Pubitemid 40790161)
17. Zhang C, Peng W, Jiang X, Chen B, Zhu J, Zang Y, et al. Transgene expression of human PON1 Q in mice protected the liver against CCl4- induced injury. J Gene Med 2008;10:94-100.
18. Marsillach J, Camps J, Ferré N, Beltran R, Rull A, Mackness B, et al. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterol 2009;9:3.
19. Schiavon R, de Fanti E, Giavarina D, Biasioli S, Cavalcanti G, Guidi G. Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta 1996;247:71-80. (Pubitemid 26101430)
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
21. Ruiz J, Blanché H, James RW, Garin MC, Vaisse C, Charpentier G, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-872
22. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995;96:3005-3008
23. Boright AP, Connelly PW, Howard Brunt J, Scherer SW, Tsui LC, Hegele RA. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 1998;139:131-136 (Pubitemid 28341875)
24. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q3R genetic polymorphism. J Lipid Res 1999;40:133-139 (Pubitemid 29022595)
25. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Gln and Arg selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000;101:2510-2517
26. Ferré N, Camps J, Cabré M, Paul, A, Joven J. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 2001;9:997-1000. (Pubitemid 32904153)
27. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc Natl Acad Sci U S A 2001;98:9599-9604 (Pubitemid 32769349)
28. Swietek K, Jusczcyk J. Reduced concentration in erythrocytes of patients with acute and chronic viral hepatitis. J Viral Hepat 1997;4:139-141 (Pubitemid 127736549)
29. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, et al. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000;33:616-622
30. Dikici I, Mehmetoglu I, Dikici N, Bitirgen M, Kurban S. Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-alpha treatment. Clin Biochem 2005;38:1141-1144 (Pubitemid 41799605)
31. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002;122:366-375 (Pubitemid 34116988)
32. Keskin M, Dolar E, Dirican M, Kiyici M, Yilmaz Y, Gurel S, et al. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity. Intern Med J 2009;39:243-248